| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10039136 | HBV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS30073496 | HIV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS30073497 | HIV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20011278 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029983 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029984 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029985 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029986 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20029987 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
| TVIS20064469 | HPV | ENSG00000147246.10 | protein_coding | HTR2C | No | No | 3358 | P28335 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2C |
|---|---|
| DrugBank ID | DB00246 |
| Drug Name | Ziprasidone |
| Target ID | BE0000533 |
| UniProt ID | P28335 |
| Regulation Type | antagonist |
| PubMed IDs | 14728084; 11103883; 7562537; 11132243; 16918396; 14638642 |
| Citations | Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12.@@Sanchez C, Arnt J: In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav Pharmacol. 2000 Jun;11(3-4):291-8.@@Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.@@Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.@@Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52.@@Cates ME: Ziprasidone--not an option for serotonin syndrome. CMAJ. 2003 Nov 25;169(11):1147-8. |
| Groups | Approved |
| Direct Classification | N-arylpiperazines |
| SMILES | ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1 |
| Pathways | |
| PharmGKB | PA451974 |
| ChEMBL | CHEMBL708 |
